Sixteen Japanese subjects (6 adults/10 children) with peri- and post-operative pulmonary hypertension associated with cardiac surgery will be evaluated at approx. 6 sites for safety and efficacy of IK-3001.
This is a multi-center, open-label, clinical study of the safety and efficacy of IK-3001 in 16 subjects with peri- and post-operative pulmonary hypertension associated with cardiac surgery. Two primary sub-sets of this patient population will be evaluated in this study: 1. Adults with severe congestive heart failure having LVAD implant 2. Children requiring surgery for congenital heart disease with corresponding PH or having Glenn surgery or Fontan surgery for single-ventricle physiology. Children with severe pulmonary hypertension due to congenital heart disease who require inhaled nitric oxide (iNO) pre-operatively may also be enrolled.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Osaka University Hospital
Osaka, Japan
National Cerebral and Cardiovascular Center (Pediatric CV Surgery)
Osaka, Japan
National Cerebral and Cardiovascular Center (Transplantation)
Osaka, Japan
The University of Tokyo Hospital
Tokyo, Japan
Change in mean pulmonary artery pressure (mPAP) in Adult subjects (with LVAD)
Time frame: Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy
Change in partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio in Adult subjects (with LVAD)
Time frame: Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy
Change in central venous pressure (CVP) in Children (with congenital heart disease)
Time frame: Predose baseline to 24 hours (or final observation, if < 24 hours)(measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy
Change in partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio in Children (with congenital heart disease)
Time frame: Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
National Center for Child Health and Development
Tokyo, Japan
Tokyo Women's Medical University Hospital
Tokyo, Japan
Tokyo Metropolitan Children's Medical Center
Tokyo, Japan